Guan, Zhou
Dai, Si-Min
Zhou, Jie
Ren, Xiao-Bing
Qin, Zhi-Qiang
Li, Yin-Long
Lv, Shan
Li, Shi-Zhu
Zhou, Xiao-Nong
Xu, Jing
Funding for this research was provided by:
National Major Science and Technology Projects of China (2018ZX10101002-002, 2012ZX10004-220)
The National Key Research and Development Program of China (2016YFC1202000)
Article History
Received: 30 November 2019
Accepted: 28 May 2020
First Online: 1 June 2020
Ethics approval and consent to participate
: Ethical clearance had been granted by the Ethics Committee of the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention in Shanghai, P. R. China (20170717). During these meetings, all participants were informed about the objectives of the study, the study procedures, sampling, study benefits, and potential risks and discomforts. All adult participants gave informed consent, and informed consent for all children who participated in the study was sought from parents or legal guardians. Assent was sought from all participants who were also informed of their rights to refuse to participate in this study and to withdraw from the study at any time. Participants with positive PCR results received free treatments with a standard dose of praziquantel.
: Not applicable.
: The authors declare that they have no competing interests.